Acquisition of Navilyst Medical Investor Conference Call |

Acquisition of Navilyst Medical

Investor Conference Call | January 31, 2012

Forward-Looking Statements

This document includes "forward-looking statements" intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995.

Investors can identify these statements by the fact that they do not relate strictly to historical or current facts. These statements contain words such as "expect," "reaffirm,"

"anticipate," "plan," "believe," "estimate," "may," "will," "predict," "project," "might," "intend," "potential," "could," "would," "should," "optimistic," "seek," "continue," "pursue,"

or "our future success depends," or the negative or other variations thereof or comparable terminology, are intended to identify such forward-looking statements. In particular,

they include statements relating to, among other things, future actions, strategies, future performance and future financial results of AngioDynamics. These forward-looking

statements are based on current expectations and projections about future events. The forward-looking statements in this document include those with respect to the expected

timing of the completion of the transaction.

Investors are cautioned that forward-looking statements are not guarantees of future performance or results and involve risks and uncertainties that cannot be predicted or

quantified and, consequently, the actual performance or results of AngioDynamics may differ materially from those expressed or implied by such forward-looking statements. Such

risks and uncertainties include, but are not limited to, the factors described from time to time in AngioDynamics' reports filed with the SEC, including AngioDynamics' Form 10-K for

the fiscal year ended May 31, 2011 and AngioDynamics' Form 10-Q for the quarterly period ended November 30, 2011; the ability of AngioDynamics to develop its existing and new

products; financial community and rating agency perceptions of AngioDynamics; third-party relations and approvals; technological advances and patents attained by competitors;

challenges inherent in new product development, including obtaining regulatory approvals; the ability of AngioDynamics to develop its products; future actions by the FDA or other

regulatory agencies; domestic and foreign health care reforms and governmental laws and regulations; results of pending or future clinical trials; overall economic conditions; the

results of ongoing litigation; the effects of economic, credit and capital market conditions on the economy in general, and on medical device companies in particular; general market

conditions; market acceptance; foreign currency exchange rate fluctuations; the effects on pricing from group purchasing organizations and competition and the ability of

AngioDynamics to integrate purchased businesses. Risk and uncertainties related to the proposed transaction include, but are not limited to delays in or failure to obtain any

required governmental and regulatory approvals with respect to the transaction; failure to obtain stockholder approval of the issuance of the AngioDynamics common stock in

connection with the transaction; failure to consummate or delay in consummating the transaction for other reasons; the possibility that the expected benefits of the transaction,

including projected synergies and tax benefits, may not materialize as expected; disruption from the proposed transaction making it more difficult to maintain business and

operational relationships; and the failure to successfully integrate the products, R&D capabilities, infrastructure and employees of AngioDynamics and Navilyst.

Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims

any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date

stated, or if no date is stated, as of the date of this document.

Additional Information

AngioDynamics intends to file with the Securities and Exchange Commission (the "SEC") a proxy statement regarding the issuance of the AngioDynamics common stock in

connection with the proposed transaction. The proxy statement will be mailed to AngioDynamics' stockholders. INVESTORS AND STOCKHOLDERS ARE ENCOURAGED TO READ THE

PROXY STATEMENT AND OTHER RELEVANT MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ANGIODYNAMICS AND

THE PROPOSED TRANSACTION. Investors and stockholders will also be able to obtain a free copy of these documents (when they are available), as well as other filings made by

AngioDynamics, without charge, at the SEC's web site at http://www.sec.gov. In addition, the documents filed by AngioDynamics with the SEC may be obtained free of charge by

contacting AngioDynamics' investor relations firm: EVC Group, 60 East 42nd Street, Suite 936, New York, NY 10165.

AngioDynamics, Avista Capital Partners, Navilyst Medical and their respective executive officers, directors and other persons may be deemed to be participants in the solicitation of

proxies from AngioDynamics' stockholders with respect to the issuance of the AngioDynamics common stock in connection with the proposed transaction. Information regarding

the officers and directors of AngioDynamics and their ownership of AngioDynamics common stock is set forth in AngioDynamics' proxy statement for its most recent annual

meeting, which was filed with the SEC on September 6, 2011. Other information regarding the participants in the solicitation and a description of their direct and indirect interests,

by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC regarding the issuance of the AngioDynamics

common stock in connection with the proposed transaction.

Overview of Navilyst

CY 2011 Revenue: $149M

Navilyst Medical is a global medical

device company focused on vascular access,

interventional radiology and interventional

Acquired by Avista Capital Partners

from Boston Scientific in February 2008

$149 million of sales in CY 2011

- Marlborough, Mass. - Headquarters , including R&D,

- Glens Falls, N.Y. - Manufacturing and Distribution;

Navilyst Adds to AngioDynamics

Broad Portfolio of Respected Brands Enhances Competitiveness

PICCs and Ports Market Presence

Full Line of Vascular Access Products

Fluid Management Leadership Provides Entr e into the Cath Lab

NAMIC Fluid Management Components

NAMIC has been the "gold standard" in

fluid management for the past 40 years

Broadest line of products available,

Loyal customer base due to quality

reputation and customization

Interventional cardiologists represent 11

million procedures or 85% of market

Navilyst Fluid Management Business

Compelling Products and Enabling Platforms - PASV Valve

PASV - A Sustainable Competitive Advantage

Patent protected: Pressure Activated Safety Valve

- Proximal 3-way valve

- Direction specific and pressure activated

Clinically proven benefits for both patients and hospitals

- Reduced risk for intraluminal occlusion

- Less use of thrombolytics

- Reduced bloodstream infection

- Effective change to saline-only flushing

- Reduced cost of care and maintenance

- Long-term reliability with +10 years of history

Proprietary technology drives premium pricing

Compelling Products and Enabling Platforms - BioFlo

BioFlo Platform - High Upside Potential

Venous thrombosis continues to be of concern

- Thrombosis rates are as high as 23%

- DVT complications are increasing

- Current offerings have significant limitations

BioFlo technology is

- NOT a coating, impregnated agent or active ingredient

- NOT eluting or transient

BioFlo is a non-stick polymer with clinically proven, long-

term thromboresistant properties

- 87% reduction in thrombus accumulation

BioFlo can be used with PICCs, Ports and Dialysis Catheters

BioFlo is approved for use in Canada and Europe and

pending clearance in the US

Operational Excellence

Forging a "Continuous Improvement" Culture

Sourcing (economies of scale)

Electromechanical Assembly

Sourcing (economies of scale) Custom Kitting

Injection Molding Lean Practices

Robust ERP & Document Mgt. Six Sigma Operations

Improved Financial Performance